Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 4/20 | 0.54 |
| ▸ | MMP1 | P03956 | 3/20 | 0.54 |
| ▸ | MMP8 | P22894 | 3/20 | 0.54 |
| ▸ | MMP9 | P14780 | 2/20 | 0.54 |
| ▸ | ACE | P12821 | 2/20 | 0.49 |
| ▸ | CCKBR | P32239 | 8/20 | 0.48 |
| ▸ | CCKAR | P32238 | 2/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30533182 | 0.89 | EDNRA (0.71) | EDNRAMMP2MMP1MMP8MMP9 | |
| SCHEMBL30533201 | 0.86 | EDNRA (0.67) | EDNRAMMP2MMP1MMP8MMP9 | |
| SCHEMBL30999648 | 0.85 | CCKBR (0.62) | CCKBRCCKAR | |
| SCHEMBL18328829 | 0.85 | CTSL (0.49) | EDNRAMMP2MMP1MMP8MMP9 | |
| SCHEMBL21481062 | 0.85 | CTSL (0.49) | EDNRAMMP2MMP1MMP8MMP9 | |
| SCHEMBL1548820 | 0.85 | CTSL (0.49) | EDNRAMMP2MMP1MMP8MMP9 | |
| SCHEMBL30046082 | 0.85 | EDNRA (0.69) | EDNRAMMP2MMP1MMP8MMP9 | |
| SCHEMBL29861978 | 0.85 | TACR1 (0.52) | ACETACR1 | |
| SCHEMBL26421785 | 0.85 | EDNRA (0.47) | EDNRAMMP2MMP1MMP8MMP9 | |
| SCHEMBL30490008 | 0.84 | TACR1 (0.51) | MMP2MMP8MMP9TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | CD2BP2, CD2, CD47 | EDNRA 2106/4885MMP2 1511/4885MMP1 3938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.